The above detailed alterations in IDO expression, IDO activity, various downstream l-kynurenine metabolite levels, as well as the global AHR activity in the acute phases of MS indicate their potential utility as biomarkers of underlying disease severity and surrogate markers of therapeutic response in future clinical trials. Here, IDO1 is linked to myeloid sarcoma.